UMAX^® | Sonocrystallization | DISCUS^® | Ultrasonic Particle Rounding | CrystalGEM^® | Intellectual Property | FDA Quality by Design

Prosonix intellectual property is a valuable asset that underpins its past, present and future success. The company aims to secure multi-layered registered protection for its products, processes and technology platforms. Prosonix patent portfolio includes over 20 families of patents and patent applications, covering inventions made internally as well as inventions in-licensed from third parties. Prosonix actively maintains and protects this patent estate. Additional value continues to be obtained from the intellectual property estate from licensing rights for the development of both pulmonary and oral products.

• Process for improving crystallinity of Fluticasone compounds: Ruecroft. G.; Parikh. D.; Hipkiss, D.; WO 2010/007446
• Process for improving crystallinity: Ruecroft. G.; Parikh. D.; Hipkiss, D.; WO 2010/007447
• Entrainment in anti-solvent: Ruecroft, G.; Robinson, J.; WO 2008/114052
• Crystalline particles using immiscible anti-solvent:solvent: Ruecroft, G.; Robinson, J.; Parikh, D. WO 2008/155570
• University of Bath patent licensed to and maintained by Prosonix: Price R, Kaerger S. J, WO 2004/073827

Exclusively in-licensed to Prosonix

• 
  Kaully T, Keren B, Kimmel T, Dekel O, WO 2000/041984
  Kaully T, Yaskin-Harush M, Nadiv C, Tenenbaum Z, Sides Y, Shacham D, WO 2006/103672

Additional Prosonix patents:

• Perkins J, WO 2000/35579
• Bowe, McCausland, Stairmand, WO 2002/089942
• McCausland L, Perkins J, WO 2003/101578
• McCausland, Reay, WO 2003/092851
• Buckley, Stairmand, US 6589500 (2003)
• Buckley, Stairmand, Bowe, US 0168330 (2003)
• McCausland L, WO 2003/101577
• McCausland L, US 0163683 (2005)
• McCausland L, Fennell M, WO 2005/123589
• McCausland L, Fennell M, WO 2005/085136
• McCausland L, Maxted N, WO 2006/003474
• McCausland L, Fennell M, WO 2006/003470
• Weeks D.M, WO 2006/087585

The following references are provided to enable a more complete understanding of our capabilities:

• Improving The Bayer Process by Power Ultrasound Induced Crystallization (sonocrystallization) of Key Impurities (2 published papers): Ruecroft, G.*; Hipkiss, D.; Fennell, M. TMS 2005, TMS Light Metals, Feb 2005 and Ruecroft, G.*; Hipkiss, D., Fennell, M., Ly, T. Proc. 7th Int. Alumina Quality Workshop, Oct 2005.
• Sonocrystallization: The use of Ultrasound in Industrial Crystallization: Ruecroft, G.*; Hipkiss, D.; Ly, T.; Cains, P. W. Org. Process Res. Dev. 2005, 9 (6), 923.
• A Resounding Success (Power Ultrasound in Drug Crystallization and Delivery): Ruecroft, G.; Manufacturing Chemist, June 2006, 41.
• Sound Science and Crystals: Improved Crystallization and Particle Engineering: Ruecroft, G.; CheManager, Production, Europe 1/2007, page 7, and Screening: Trends in Drug Discovery 2/2007, April, 8, 34.
• Sonocrystallisation to the Rescue: Ruecroft, G.; Innovations in Pharmaceutical Technologies, 2007, 22 (Spring), 74.
• Ultrasound, crystallization and drug formulation: Ruecroft, G.; Speciality Chemicals Magazine, 2007, 27 (5), 64.
• Power ultrasound and particle engineering: Ruecroft, G.; chimica oggi – Chemistry Today, 2007, 25 (3), 12.
• Sound science in molecules &particles: Ruecroft, G.; Speciality Chemicals Magazine, June 2008, 54.
• Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions: Ruecroft, G*.; Parikh, D.; Pharmaceutical Technology Supplement, September 2008.
• Improving the delivery of inhalable medicines Ultrasound assisted particle engineering of respiratory  microcrystals: Ruecroft. G.; Shur. J.; Chimica Oggi / Chemistry Today, Focus on Excipients; 2009, 27 (5), 25-28.